Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
This Phase I open-label study evaluates the pharmacokinetics of warfarin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of warfarin.
Age
18–55
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
male healthy volunteers in good health
no clinically significant diseases or clinically significant abnormal laboratory values
body mass index (BMI) is \>/=18 kg and ≤30 kg/m2
nonsmoker
You may not be if
positive test results for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
any clinically relevant abnormality
history of any anaphylactic reaction to any drug
history of significant cardiovascular or pulmonary dysfunction
history of excessive bleeding
current or chronic history of liver disease
history of alcohol or substance abuse
history of thyroid disease or dysfunction
history of gastrointestinal surgery or disease
history of pancreatitis
previously received any GLP-1 mimetic compound (e.g., exenatide)
